Recurrence Rates - The KD Encore
-
Recurrence vs. Recrudescence
- Recurrence: A new, distinct episode of Kawasaki Disease (KD) after complete recovery.
- Recrudescence: Relapse of fever and symptoms within days of initial IVIG, indicating treatment resistance.
-
Incidence & Timeline
- Overall rate is low: ~1-3%.
- Most recurrences (>50%) happen within 2 years of the initial episode.
- Risk may be higher in patients who required a second dose of IVIG.
⭐ High-Yield Fact: Patients who develop coronary artery abnormalities (CAA) during their first KD episode are at a significantly higher risk for recurrence compared to those without CAA.
Risk Factors - Predicting a Relapse
-
Host-Related Factors:
- Male sex
- Age < 1 year at onset
- Genetic predisposition (e.g., ITPKC polymorphisms)
-
Treatment & Disease Course:
- Delayed IVIG therapy (> 10 days of fever)
- Resistance to initial IVIG treatment
- Severe initial inflammation (↑ CRP, ↑ ESR)
- Presence of coronary artery lesions (CALs) during the first episode
⭐ Patients resistant to initial IVIG therapy have a significantly higher risk of developing coronary artery aneurysms and subsequent recurrence.
Diagnosis & Features - Spotting the Sequel
-
High Index of Suspicion: Essential for any patient with a history of Kawasaki Disease (KD) presenting with unexplained fever.
-
AHA Criteria for Recurrence:
- Unexplained fever reappears and lasts ≥48 hours.
- Accompanied by ≥3 of the original principal clinical criteria.
- If fever is present with <3 criteria, evaluate for incomplete recurrent KD.
-
Role of Echocardiography:
- Absolutely critical at the time of suspected recurrence.
- Aims to detect new or worsening coronary artery abnormalities (CAA).
⭐ Recurrence risk is highest within the first 2 years of the initial illness and is more common in patients who had cardiac complications initially.
Management - The Retreatment Playbook
- Standard First-Line: IVIG 2 g/kg as a single infusion + high-dose aspirin.
- IVIG-Resistant KD: Persistent or recrudescent fever ≥36 hours after initial IVIG.
- Aspirin Regimen:
- Anti-inflammatory: 80-100 mg/kg/day until afebrile for 48-72 hrs.
- Anti-platelet: Taper to 3-5 mg/kg/day for 6-8 weeks (or longer if coronary abnormalities).
⭐ Infliximab (5-10 mg/kg), a TNF-α inhibitor, is a key second-line agent, especially effective in refractory cases and for rapid control of inflammation.
High‑Yield Points - ⚡ Biggest Takeaways
- Recurrence of Kawasaki Disease (KD) is uncommon (approx. 1-3%), with most cases occurring within 2 years of the initial episode.
- Major risk factors for recurrence include male sex, age <1 year, and significant cardiac involvement during the first illness.
- Recurrent episodes are often milder and carry a lower risk of developing new coronary artery aneurysms.
- Management of a recurrent episode is identical to the primary one: high-dose IVIG and aspirin.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app